Breast Cancer

The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.

In a proof-of-concept study, the group has demonstrated its platform could detect a biomarker of breast tumor metastasis and other disease biomarkers.

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.

In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto. 

The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.